ID   Mel Cher
AC   CVCL_B6K8
SY   mel Cher
DR   cancercelllines; CVCL_B6K8
DR   Wikidata; Q112129263
RX   CelloPub=CLPUB00680;
RX   CelloPub=CLPUB00681;
RX   DOI=10.17650/1726-9784-2016-15-3-90-94;
RX   DOI=10.17650/1726-9784-2018-17-4-27-35;
RX   Patent=RU2364624;
RX   Patent=RU2404243;
RX   PubMed=16107020;
RX   PubMed=27313776;
RX   PubMed=28881731;
CC   Group: Patented cell line.
CC   Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 704D.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680; DOI=10.17650/1726-9784-2018-17-4-27-35).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=28881731).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   CelloPub=CLPUB00680;
RA   Mikhailova I.N., Baryshnikov A.Y., Morozova L.F., Burova O.S.,
RA   Shubina I.Z., Kovalevsky D.A., Voronina E.S., Treshalina H.M.,
RA   Lushnikova A.A., Tsyganova I.V., Mazurenko N.N.;
RT   "Human skin melanoma cell lines collection.";
RL   (In) Management of malignant melanoma; pp.1-6; SM Group; Dover (2016).
//
RX   CelloPub=CLPUB00681;
RA   Berezhnoy A.E., Zakeyeva I.R., Kibardin A.V., Chernysheva A.D.,
RA   Moiseyenko V.M., Danilov A.O., Demidov L.V., Baryshnikov A.Y.,
RA   Gnuchev N.V., Georgiev G.P., Larin S.S.;
RT   "Analysis of HLA-E expression in human melanoma cells.";
RL   Ross. Bioterap. Zh. 5:66-71(2006).
//
RX   DOI=10.17650/1726-9784-2016-15-3-90-94;
RA   Morozova L.F., Suraeva N.M., Burova O.S., Barmashov A.E.,
RA   Baryshnikova M.A.;
RT   "Changes in the morphological and immunological characteristics of
RT   Mel Cher melanoma cells in response to low concentration of embryo
RT   calf serum.";
RL   Ross. Bioterap. Zh. 15:90-94(2016).
//
RX   DOI=10.17650/1726-9784-2018-17-4-27-35;
RA   Mikhailova I.N., Treshalina E.M., Morozova L.F., Andronova N.V.,
RA   Shubina I.Z., Lushnikova A.A.;
RT   "Cell lines of human melanoma and their xenograft with BRAF or NRAS
RT   mutations a targets for targeted therapy.";
RL   Ross. Bioterap. Zh. 17:27-35(2018).
//
RX   Patent=RU2364624;
RA   Mikhailova I.N., Baryshnikov A.Y., Demidov L.V., Kiselev S.L.,
RA   Burova O.S., Morozova L.F.;
RT   "Cell line of human melanoma mel Cher, used for obtaining anti-tumour
RT   vaccines.";
RL   Patent number RU2364624, 20-Aug-2009.
//
RX   Patent=RU2404243;
RA   Grigorieva I.N., Stepanova E.V., Vartanjan A.A., Baryshnikov A.Y.,
RA   Mikhailova I.N., Morozova L.F., Burova O.S.;
RT   "Application of human skin melanoma cell line mel Cher as positive
RT   model of vasculogenic mimicry.";
RL   Patent number RU2404243, 20-Nov-2010.
//
RX   PubMed=16107020;
RA   Mikhailova I.N., Lukashina M.I., Baryshnikov A.Y., Morozova L.F.,
RA   Burova O.S., Palkina T.N., Kozlov A.M., Golubeva V.A.,
RA   Cheremushkin E.A., Doroshenko M.B., Demidov L.V., Kiselev S.L.,
RA   Larin S.S., Georgiev G.P.;
RT   "Melanoma cell lines as the basis for antitumor vaccine preparation.";
RL   Vestn. Ross. Akad. Med. Nauk 2005:37-40(2005).
//
RX   PubMed=27313776; DOI=10.3892/ol.2016.4523;
RA   Vartanian A.A., Karshieva S., Dombrovsky V., Belyavsky A.;
RT   "Melanoma educates mesenchymal stromal cells towards vasculogenic
RT   mimicry.";
RL   Oncol. Lett. 11:4264-4268(2016).
//
RX   PubMed=28881731; DOI=10.18632/oncotarget.17014;
RA   Emelyanova M., Ghukasyan L., Abramov I., Ryabaya O., Stepanova E.V.,
RA   Kudryavtseva A., Sadritdinova A., Dzhumakova C., Belysheva T.,
RA   Surzhikov S., Lyubchenko L., Zasedatelev A., Nasedkina T.;
RT   "Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in
RT   Russian melanoma patients using LNA PCR clamp and biochip analysis.";
RL   Oncotarget 8:52304-52320(2017).
//